The SpyGlass Drug Delivery Platform combines safe, lasting treatment with the world's most common, routine ophthalmic surgery.
Spyglass Platform Pipeline
February 2023 – SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco. (View full press release)